Suchergebnisse - "Sala, Luca"

PubPharm (5)

1

Therapy of Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia : Is There an Optimal Interleukin 6 Cutoff for Successful Tocilizumab Treatment?

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2021

von Squillace, N. | Pozzi, M. | Gustinetti, G. | +5

2

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50

enthalten in: Cancer immunology, immunotherapy : CII | 2020

von Cortellini, A. | Tiseo, M. | Banna, G. | +67

3

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes

enthalten in: Clinical lung cancer | 2020

von Cortellini, A. | Friedlaender, A. | Banna, G. | +68

4

Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

enthalten in: Journal of translational medicine | 2020

von Perrone, F. | Piccirillo, M. | Ascierto, P. | +134

ErratumIn: J Transl Med. 2021 Oct 21;19(1):442. - PMID 34674735

5

Disseminated intravascular coagulation in advanced lung adenocarcinoma during first-line pembrolizumab

enthalten in: Immunotherapy | 2020

von Alberti, A. | Mancin, M. | Cortinovis, D. | +2

1
[1]